ErkutBahceciMD

PubMed

• 25 citations
  Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.
  Catherine C Smith, Mark J Levis, Alexander E Perl, Jason E Hill, Matt Rosales, Erkut Bahceci> ;Blood Advances. 2022 Apr 12
• 1 citations
  Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
  Angela Joubert James, Catherine C. Smith, Mark R. Litzow, Alexander E. Perl, Jessica K. Altman, Dale R. Shepard, Takeshi Kadokura, Kinya Souda, Melanie Patton, Zheng L...> ;Clinical Pharmacokinetics. 2021 Jul 23
• 1 citations
  Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.
  Akira Ono, Haruyasu Murakami, Takashi Seto, Toshio Shimizu, Sawori Watanabe, Shigeru Takeshita, Kentaro Takeda, Junko Toyoshima, Itsuro Nagase, Erkut Bahceci, Maiko Mo...> ;Drugs in R&D. 2021 Mar 1
• 7 citations
  The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory...
  Jessica K. Altman, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci, Mark J. Levis> ;Cancer Medicine. 2021 Feb 1
• 36 citations
  Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
  Angela Joubert James, Catherine C. Smith, Mark R. Litzow, Alexander E. Perl, Jessica K. Altman, Dale R. Shepard, Takeshi Kadokura, Kinya Souda, Melanie Patton, Zheng L...> ;Clinical Pharmacokinetics. 2020 Oct 1
• 44 citations
  Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
  Theodore C. Tarver, Jason E. Hill, Leena T. Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith> ;Blood Advances. 2020 Feb 11
• 37 citations
  Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study
  Kensuke Usuki, Toru Sakura, Yukio Kobayashi, Toshihiro Miyamoto, Hiroatsu Iida, Satoshi Morita, Erkut Bahceci, Masahito Kaneko, Mikiko Kusano, Shunsuke Yamada, Shigeru...> ;Cancer Science. 2018 Oct 1
• 85 citations
  A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
  Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timot...> ;Blood Advances. 2018 Apr 24
• 336 citations
  Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
  Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Mark R. Litzow, Maria R. Baer, David F. Claxton, Harry P. Erba, Stan Gill, Stuart L. Goldber...> ;The Lancet. Oncology. 2017 Aug 1
• 14 citations
  The Patient Perspective on Living with Acute Myeloid Leukemia
  Erin L. Tomaszewski, Catherine E. Fickley, LeAnne Maddux, Robert Krupnick, Erkut Bahceci, Jean Paty, Floortje van Nooten> ;Oncology and Therapy. 2016 Sep 2
• 18 citations
  First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients...
  Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony W. Tolcher> ;Journal of Hematology & Oncology. 2016 Mar 10
• 28 citations
  Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF
  Andreas Lundqvist, Aleah Smith, Yoshiyuki Takahashi, Susan Wong, Erkut Bahceci, Lisa Cook, Catalina Ramos, Abdul Tawab, J. Philip McCoy, Elizabeth J. Read, Hanh Khuu, ...> ;Journal of Immunology. 2013 Dec 15
• 298 citations
  Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease
  Partow Kebriaei, Luis Isola, Erkut Bahceci, Kent Holland, Scott D. Rowley, Joseph McGuirk, Marcel P. Devetten, Jan Jansen, Roger H. Herzig, Michael W. Schuster, Rod Mo...> ;Biology of Blood and Marrow Transplantation. 2009 Jul 1
• 44 citations
  Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes
  Peter M. Rabinovich, Marina E. Komarovskaya, Stephen H. Wrzesinski, Jonathan Alderman, Tulin Budak-Alpdogan, Alexander Karpikov, Hongfen Guo, Richard A. Flavell, Nai-K...> ;Human Gene Therapy. 2008 Oct 15
• 55 citations
  Synthetic Messenger RNA as a Tool for Gene Therapy
  Peter M. Rabinovich, Marina E. Komarovskaya, Zhi-jia Ye, Chihaya Imai, Dario Campana, Erkut Bahceci, Sherman M. Weissman> ;Human Gene Therapy. 2006 Oct 10
• 44 citations
  A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis.
  Ryotaro Nakamura, Sakti Chakrabarti, Cem Akin, Jamie Robyn, Erkut Bahceci, A Greene, Richard W. Childs, Cynthia E. Dunbar, Dean D. Metcalfe, Austin John Barrett> ;Bone Marrow Transplantation. 2006 Feb 1
• 15 citations
  Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
  Stuart Seropian, Erkut Bahceci, Dennis L. Cooper> ;Bone Marrow Transplantation. 2003 Oct 1
• 37 citations
  Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected...
  Erkut Bahceci, Diane E. Epperson, Daniel C. Douek, J. Joseph Melenhorst, Richard C. Childs, A. John Barrett> ;British Journal of Haematology. 2003 Sep 1
• 165 citations
  Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes
  Jeffrey J. Molldrem, Eric Leifer, Erkut Bahceci, Yogen Saunthararajah, Mary Rivera, Cynthia E. Dunbar, Johnson Liu, Riotoro Nakamura, Neal S. Young, A. John Barrett> ;Annals of Internal Medicine. 2002 Aug 6
• 55 citations
  Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transpl...
  Ryotaro Nakamura, Erkut Bahceci, Elizabeth J. Read, Susan F. Leitman, Charles S. Carter, Richard W. Childs, Cynthia E. Dunbar, Ronald E. Gress, Rosemary M. Altemus, Ne...> ;British Journal of Haematology. 2001 Oct 1
• 59 citations
  CD34+ cell dose predicts relapse and survival after T‐cell‐depleted HLA‐identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies
  E. Bahceci, Elizabeth J. Read, Susan F. Leitman, Richard W. Childs, Cynthia E. Dunbar, Neal S. Young, Austin John Barrett> ;British Journal of Haematology. 2000 Feb 1
• 451 citations
  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.
  Richard W. Childs, Emmanuel Clave, N. Contentin, D. Jayasekera, Nancy F. Hensel, Susan F. Leitman, Elizabeth J. Read, Corey A. Carter, E. Bahceci, Neal S. Young, Austi...> ;Blood. 1999 Nov 1
• 34 citations
  Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a gr...
  Richard W. Childs, Diane E. Epperson, E. Bahceci, Emmanuel Clave, J. Barrett> ;British Journal of Haematology. 1999 Nov 1
• Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
  Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., Young, N. S., Barrett, A. J.> ;N Engl J Med. 2000 Sep 14
• Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC tran...
  Solomon, S. R., Tran, T., Carter, C. S., Donnelly, S., Hensel, N., Schindler, J., Bahceci, E., Ghetie, V., Michálek, J., Mavroudis, D., Read, E. J., Vitetta, E. S., Ba...> ;Cytotherapy. 2002
• Join now to see all